Publication: 2830

Publication: 2830

Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial

URL

URL

Google Scholar

Citation:: J Clin Oncol vol 36 (suppl 6S) abstr 582

Meeting Instance:: ASCO GU 2018
Year:: 2018
Type:: Abstract
Sub type:: Oral
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: No
SDC:: No

Parents:: None
Children:: 2834

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882

Corr. Author:
Authors:: Daniel George Colin Hessel Susan Halabi Ben Sanford M. Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Shaker Dakhil Darren Feldman Milan Mangeshkar Christian Scheffold Michael J. Morris Toni K. Choueiri

Networks:: CA824, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007

Study: Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: